4//SEC Filing
Quaker BioVentures II LP 4
Accession 0001192482-19-000430
CIK 0001561921other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 9:03 PM ET
Size
19.2 KB
Accession
0001192482-19-000430
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Quaker BioVentures II LP
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2019-11-13−12,763,434→ 0 total→ Common Stock (516,947 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 0 totalExercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (446,813 underlying) - Purchase
Common Stock
2019-11-08$13.00/sh+153,846$1,999,998→ 888,664 total - Conversion
Common Stock
2019-11-13+345,489→ 1,234,153 total - Conversion
Common Stock
2019-11-13+516,947→ 1,751,100 total - Conversion
Series A Preferred Stock
2019-11-13−8,530,145→ 0 total→ Common Stock (345,489 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 446,813 totalExercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (18,096 underlying)
Quaker BioVentures Capital II, L.P.
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2019-11-13−12,763,434→ 0 total→ Common Stock (516,947 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 446,813 totalExercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (18,096 underlying) - Purchase
Common Stock
2019-11-08$13.00/sh+153,846$1,999,998→ 888,664 total - Conversion
Common Stock
2019-11-13+345,489→ 1,234,153 total - Conversion
Common Stock
2019-11-13+516,947→ 1,751,100 total - Conversion
Series A Preferred Stock
2019-11-13−8,530,145→ 0 total→ Common Stock (345,489 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 0 totalExercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (446,813 underlying)
Footnotes (5)
- [F1]Reflects 705,530 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F2]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F3]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F5]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Documents
Issuer
TELA Bio, Inc.
CIK 0001561921
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001497725
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 9:03 PM ET
- Size
- 19.2 KB